Back to Search Start Over

Characterization of the mechanism of Scutellaria baicalensis on reversing radio-resistance in colorectal cancer

Authors :
Jinmei Huang
Ming Zhou
Huan Zhang
Yeying Fang
Gang Chen
Jiaying Wen
LiMin Liu
Source :
Translational Oncology, Vol 24, Iss , Pp 101488- (2022)
Publication Year :
2022
Publisher :
Elsevier, 2022.

Abstract

Scutellaria baicalensis (SB) has been shown to improve the therapeutic effects of colorectal cancer (CRC) and perform well for reversing radio-resistance in different cancers. However, its potential function and mechanism related to radio-resistance in CRC has not been explored. A radio-resistant human CRC cell line (HCT116R) was applied. A network pharmacological analysis was performed to reveal the potential mechanism of SB for reversing radio-resistance in CRC, and computational pathological analysis was applied to indicate the clinicopathological significance of the key targets. Then, our hypothesis was further verified by molecular docking. The network pharmacology analysis showed that wogonin is the key compound of SB for reversing the radio-resistance of CRC. A Kyoto Encyclopedia of Genes and Genomes analysis showed that the genes for SB that reverse radio-resistance in CRC are mainly involved in steroid hormone biosynthesis. An enrichment analysis pointed out that Sulfotransferase family 2B member 1 (SULT2B1) is a potentially vital gene. SULT2B1 was demonstrated as being highly expressed in CRC and upregulated in radio-resistant rectal tissues or cell lines. A CCK-8 and clone formation test showed that the viability and clone formation ability of HCT116R were significantly decreased by wogonin combined with radiotherapy, compared to radiotherapy alone. By contrast, flow cytometry revealed that the apoptosis of HCT116R was significantly increased when wogonin treatment combined with radiotherapy, compared with radiotherapy alone. Molecular docking verification indicated that SULT2B1 and wogonin have a good binding ability. Taken together, SULT2B1 may be the potential drug target in treating radio-resistant CRC. Wogonin may be the core compound of SB for reversing radio-resistance in CRC by targeting SULT2B1.

Details

Language :
English
ISSN :
19365233
Volume :
24
Issue :
101488-
Database :
Directory of Open Access Journals
Journal :
Translational Oncology
Publication Type :
Academic Journal
Accession number :
edsdoj.b9a394e554794ad6bb0ac1d373d4dd30
Document Type :
article
Full Text :
https://doi.org/10.1016/j.tranon.2022.101488